WO2003106425A3 - Phenyl- et pyridyl-diazaheterocycles ayant une activite modulatrice du tnf - Google Patents

Phenyl- et pyridyl-diazaheterocycles ayant une activite modulatrice du tnf Download PDF

Info

Publication number
WO2003106425A3
WO2003106425A3 PCT/FR2003/001813 FR0301813W WO03106425A3 WO 2003106425 A3 WO2003106425 A3 WO 2003106425A3 FR 0301813 W FR0301813 W FR 0301813W WO 03106425 A3 WO03106425 A3 WO 03106425A3
Authority
WO
WIPO (PCT)
Prior art keywords
diazaheterocycles
pyridyl
phenyl
modulating activity
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/001813
Other languages
English (en)
Other versions
WO2003106425A2 (fr
Inventor
Marco Baroni
Bernard Bourrie
Pierre Casellas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to AU2003263237A priority Critical patent/AU2003263237A1/en
Priority to US10/518,652 priority patent/US20050209216A1/en
Priority to EP03760042A priority patent/EP1517896A2/fr
Priority to JP2004513258A priority patent/JP2005533790A/ja
Publication of WO2003106425A2 publication Critical patent/WO2003106425A2/fr
Publication of WO2003106425A3 publication Critical patent/WO2003106425A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) dans laquelle X représente N ou CH; R1 représente un atome d'hydrogène ou d'halogène ou un groupe CF3; W représente un diazohétérocycle ; R2 et R3 représentent indépendamment un atome d'hydrogène ou un groupe méthyle; n est 0 ou 1; A représente une quinoléine ou une isoquinoléine éventuellement substituées.
PCT/FR2003/001813 2002-06-18 2003-06-16 Phenyl- et pyridyl-diazaheterocycles ayant une activite modulatrice du tnf Ceased WO2003106425A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003263237A AU2003263237A1 (en) 2002-06-18 2003-06-16 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
US10/518,652 US20050209216A1 (en) 2002-06-18 2003-06-16 Phenyl-and pyridyl-diazaheterocycles having a tnf-modulating activity
EP03760042A EP1517896A2 (fr) 2002-06-18 2003-06-16 Phenyl- et pyridyl-diazaheterocycles ayant une activite modulatrice du tnf
JP2004513258A JP2005533790A (ja) 2002-06-18 2003-06-16 Ｔｎｆ調整作用を有するフェニル−およびピリジル−ジアザ複素環

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207507A FR2840896B1 (fr) 2002-06-18 2002-06-18 Phenyl-et pyridyl-piperazines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR02/07507 2002-06-18

Publications (2)

Publication Number Publication Date
WO2003106425A2 WO2003106425A2 (fr) 2003-12-24
WO2003106425A3 true WO2003106425A3 (fr) 2004-04-01

Family

ID=29595360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/001813 Ceased WO2003106425A2 (fr) 2002-06-18 2003-06-16 Phenyl- et pyridyl-diazaheterocycles ayant une activite modulatrice du tnf

Country Status (6)

Country Link
US (1) US20050209216A1 (fr)
EP (1) EP1517896A2 (fr)
JP (1) JP2005533790A (fr)
AU (1) AU2003263237A1 (fr)
FR (1) FR2840896B1 (fr)
WO (1) WO2003106425A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544657A (en) * 1983-05-19 1985-10-01 Hoffmann-La Roche Inc. Substituted isoquinolines
FR2736053A1 (fr) * 1995-06-28 1997-01-03 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
WO2001029026A1 (fr) * 1999-10-22 2001-04-26 Sanofi-Synthelabo Phenyl- et pyridyl-tetrahydro-pyridines possedant une activite inhibitrice de fnt
WO2001055150A1 (fr) * 2000-01-28 2001-08-02 Sanofi-Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (fr) * 1959-09-25 1900-01-01

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544657A (en) * 1983-05-19 1985-10-01 Hoffmann-La Roche Inc. Substituted isoquinolines
FR2736053A1 (fr) * 1995-06-28 1997-01-03 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
WO2001029026A1 (fr) * 1999-10-22 2001-04-26 Sanofi-Synthelabo Phenyl- et pyridyl-tetrahydro-pyridines possedant une activite inhibitrice de fnt
WO2001055150A1 (fr) * 2000-01-28 2001-08-02 Sanofi-Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BARLOCCO ET AL: "mon- and disubstituted-3,8-diazabicyclo(3.2.1)octane derivatives as analgesics structurally related to epibatidine: synthesis, activity and modeling", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 5, 1998, pages 674 - 681, XP002105020, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
JP2005533790A (ja) 2005-11-10
AU2003263237A1 (en) 2003-12-31
EP1517896A2 (fr) 2005-03-30
FR2840896B1 (fr) 2005-04-08
US20050209216A1 (en) 2005-09-22
WO2003106425A2 (fr) 2003-12-24
FR2840896A1 (fr) 2003-12-19
AU2003263237A8 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
MA26879A1 (fr) Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation.
FR18C1006I1 (fr) Derives de quinoline ayant un groupe azolyle et derives de quinazoline
FR2592048A1 (fr) Inhibiteurs d'ureido-renine, a action therapeutique
MA27573A1 (fr) Sinomenine et derives de sinomenine, synthese et utilisation.
MA31924B1 (fr) Derives d'oxadiazole actifs sur la sphingosine-1-phosphate (s1p)
DK0915866T3 (da) Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
TNSN06075A1 (fr) Phenyl-ou pyridylamides servant d'antagonistes de la prostaglandine e2
BG105271A (bg) Производни на 1h-имидазопиридин
TR200000896T2 (tr) Amidokarboksilik asit türevleri.
DK1117648T3 (da) Tetrahydroquinolinderivater med selektiv virkning for retinoid X receptorer
EA200000096A1 (ru) Производные арилоксиарилсульфониламиногидроксамовой кислоты
HUP0002353A2 (hu) IV típusú foszfodiészteráz inhibitor hatású 1-cikloalkil-1,8-naftiridin-4-on-származékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
FR2385713A1 (fr) Derives de 5-(4-(diarylmethyl)-1-piperazinylalkyl)benzimidazole ayant une activite antihistaminique, anti-allergique et anti-asthmatique
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
DK0464604T3 (da) 1-indolylalkyl-4-(alkoxypyrimidinyl)piperaziner
SE8800638D0 (sv) Antihypercholesterolemic tetrazole compounds
DK1447400T3 (da) Bicyklisk forbindelse
BE904587A (fr) Intermediaires intervenant dans la production d'epipodophyllotoxine et composes apparentes : procedes de preparation et emploi.
CA2201162A1 (fr) Esters phosphoriques d'alkyl ou d'acyl dianhydro-1,4:3,6-d-glucitol, procede de preparation et utilisations
MA29559B1 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
FR2380278A1 (fr) Nouvelles 1-((diarylmethyl)aminoalkyl) piperidines
ATE416174T1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
EA200100059A2 (ru) Новые бензолсульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
CO5060459A1 (es) Espiro [piperidin-4,1´-pirrolo[3,4-c]pirrol]
BE902147A (fr) Pesticides.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003760042

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004513258

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10518652

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003760042

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003760042

Country of ref document: EP